Related Experiment Video
Updated: Aug 7, 2026
10:51
Microscale Vortex-assisted Electroporator for Sequential Molecular Delivery
Published on: August 7, 2014
Low molecular weight dextran in experimental embolectomy
Stroke
|January 1, 1980
Summary
Low molecular weight dextran (LMD) significantly reduced brain infarction volume in canine middle cerebral artery (MCA) occlusion models. This treatment shows promise for mitigating ischemic stroke damage.
Area of Science:
- Neuroscience
- Cerebrovascular Research
- Ischemic Stroke Models
Background:
- Middle cerebral artery (MCA) occlusion is a common cause of ischemic stroke.
- Assessing therapeutic interventions requires reliable animal models.
- Understanding the pathophysiology of infarction is crucial for developing treatments.
Purpose of the Study:
- To evaluate the efficacy of low molecular weight dextran (LMD) in reducing brain infarction volume after MCA occlusion.
- To investigate the protective effects of LMD in a canine embolectomy model.
Main Methods:
- Canine middle cerebral artery (MCA) was embolized using a pliable cylinder.
- Embolectomy was performed 6 hours post-embolization in both control and experimental groups.
- Experimental animals received low molecular weight dextran (LMD) treatment.
Main Results:
- Control animals exhibited an average brain infarction volume of 1.45 cm³.
- Experimental animals treated with LMD showed a significantly reduced average infarction volume of 0.13 cm³.
Conclusions:
- Low molecular weight dextran (LMD) demonstrates a potent neuroprotective effect in a canine model of ischemic stroke.
- LMD treatment substantially mitigates infarct volume following middle cerebral artery (MCA) occlusion and embolectomy.
- These findings suggest LMD as a potential therapeutic agent for acute ischemic stroke.
